Elizabeth E Reed
General Counsel at Travere Therapeutics, Inc. (TVTX)
Purchase track record
Not enough history. Based on 0 purchases with a full 90 days of price history.
—
Avg. 90-day return—
vs. S&P 500—
Beat the market—
Paper profit on buys$0
Total bought / sold$0 / $7.0M
Reported trades
| Filed | Stock | Type | Shares | Price | Value | Since |
|---|---|---|---|---|---|---|
| Sep 17SEC | TVTXTravere Therapeutics, Inc. | Sell Plan | 21,926120,963 held (−15%) | $62.03 | $1.4M | -16.0% |
| Sep 17SEC | TVTXTravere Therapeutics, Inc. | Sell Plan | 13,874107,089 held (−11%) | $62.63 | $869K | -16.8% |
| Sep 17SEC | TVTXTravere Therapeutics, Inc. | Sell Plan | 1,400105,689 held (−1%) | $63.69 | $89K | -18.2% |
| Sep 17SEC | TVTXTravere Therapeutics, Inc. | Sell Plan | 300105,389 held (−0%) | $65.31 | $20K | -20.2% |
| May 6SEC | TVTXTravere Therapeutics, Inc. | Sell Plan | 20,000105,211 held (−16%) | $45.00 | $900K | +15.8% |
| May 6SEC | TVTXTravere Therapeutics, Inc. | Sell Plan | 2,174107,287 held (−2%) | $46.65 | $101K | +11.7% |
| May 6SEC | TVTXTravere Therapeutics, Inc. | Sell Plan | 2,076105,211 held (−2%) | $43.95 | $91K | +18.6% |
| Apr 15SEC | TVTXTravere Therapeutics, Inc. | Sell Plan | 37,500119,211 held (−24%) | $41.07 | $1.5M | +26.9% |
| Apr 15SEC | TVTXTravere Therapeutics, Inc. | Sell Plan | 7,215111,996 held (−6%) | $41.93 | $303K | +24.3% |
| Apr 15SEC | TVTXTravere Therapeutics, Inc. | Sell Plan | 5,226106,770 held (−5%) | $41.62 | $218K | +25.2% |
| Apr 15SEC | TVTXTravere Therapeutics, Inc. | Sell Plan | 1,559105,211 held (−1%) | $42.53 | $66K | +22.6% |
| Apr 2SEC | TVTXTravere Therapeutics, Inc. | Sell Plan | 10,000105,211 held (−9%) | $30.00 | $300K | +73.8% |
| Mar 18SEC | TVTXTravere Therapeutics, Inc. | Sell Plan | 10,000105,211 held (−9%) | $28.09 | $281K | +85.6% |
| Feb 19SEC | TVTXTravere Therapeutics, Inc. | Sell Plan | 5,679109,532 held (−5%) | $27.50 | $156K | +89.5% |
| Feb 19SEC | TVTXTravere Therapeutics, Inc. | Sell Plan | 4,321105,211 held (−4%) | $28.26 | $122K | +84.4% |
| Feb 5SEC | TVTXTravere Therapeutics, Inc. | Sell Plan | 2,485105,720 held (−2%) | $32.07 | $80K | +62.5% |
| Feb 5SEC | TVTXTravere Therapeutics, Inc. | Sell Plan | 509105,211 held (−0%) | $32.74 | $17K | +59.2% |
| Feb 3SEC | TVTXTravere Therapeutics, Inc. | Sell | 7,175108,205 held (−6%) | $32.12 | $230K | +62.3% |
| Jan 21SEC | TVTXTravere Therapeutics, Inc. | Sell Plan | 10,00090,270 held (−10%) | $27.34 | $273K | +90.7% |
- Sell
General Counsel Elizabeth E Reed sold $1.4M of TVTX at $62.03 — pre-scheduled 10b5-1 plan sale.
- Sell
General Counsel Elizabeth E Reed sold $869K of TVTX at $62.63 — pre-scheduled 10b5-1 plan sale.
- Sell
General Counsel Elizabeth E Reed sold $89K of TVTX at $63.69 — pre-scheduled 10b5-1 plan sale.
- Sell
General Counsel Elizabeth E Reed sold $20K of TVTX at $65.31 — pre-scheduled 10b5-1 plan sale.
- Sell
General Counsel Elizabeth E Reed sold $900K of TVTX at $45.00 — pre-scheduled 10b5-1 plan sale.
- Sell
General Counsel Elizabeth E Reed sold $101K of TVTX at $46.65 — pre-scheduled 10b5-1 plan sale.